The European Commission has announced the approval of a new medication for the treatment of adults with metastatic pancreatic cancer who have previously undergone treatment. The medication, Daraxonrasib, was granted marketing authorization in the EU, according to a statement released by the Commission. This new treatment option is intended for adults who have already received at least one line of prior treatment.

The Commission noted that the medication was subject to accelerated regulatory procedures under the EU's revised pharmaceutical legislation, ensuring that it meets the Union's rigorous standards for safety, quality, and efficacy. The European Medicines Agency issued a favorable scientific opinion on Daraxonrasib in just over 100 days, which is roughly half the standard deadline of 210 days. This rapid evaluation reflects the Commission's consideration that Daraxonrasib addresses a significant unmet medical need for a serious disease.

Metastatic pancreatic cancer is a severe disease that requires more effective treatment options. The approval of Daraxonrasib offers new hope for patients who have limited alternatives. According to the European Commission, this medication has the potential to provide a response to an unmet medical need. The Commission's decision is based on a thorough evaluation of the medication's benefits and risks.

Daraxonrasib is currently undergoing joint clinical evaluation by EU member states through the Coordination Group for Health Technology Assessment. This collaborative process enables countries to assess the clinical benefits of new medications and medical devices jointly, reducing duplication of efforts and streamlining the evaluation process. The report on this evaluation is expected to be released in December.

The accelerated evaluation and approval of Daraxonrasib demonstrate the European Commission's commitment to facilitating access to innovative treatments for patients with serious diseases. By expediting the evaluation process, the Commission aims to make new treatments available to patients more quickly. This approach is in line with the EU's efforts to improve the regulatory framework for pharmaceuticals.

Cabo Verde and Portugal are among the countries that will have access to Daraxonrasib as a treatment option for metastatic pancreatic cancer. The approval of this medication highlights the importance of collaboration between EU member states in evaluating and approving new treatments. Patients in these countries can expect to benefit from this new treatment option.

The European Commission's approval of Daraxonrasib was reported by RecordTV Cabo Verde and Lusa. The Commission's decision is based on a comprehensive evaluation of the medication's safety, efficacy, and quality. Daraxonrasib will provide a new treatment option for adults with metastatic pancreatic cancer who have previously undergone treatment.

Key points

  • The European Commission has authorized Daraxonrasib for the treatment of adults with metastatic pancreatic cancer who have undergone previous treatment.
  • The medication was subject to accelerated regulatory procedures under the EU's revised pharmaceutical legislation.
  • Daraxonrasib is currently undergoing joint clinical evaluation by EU member states through the Coordination Group for Health Technology Assessment.

Reporting sources

Share this story

Written by

SaharaWire Newsroom
SaharaWire

Reporting for SaharaWire from the Nairobi bureau.